CERo Therapeutics Warrants
CEROW
CEROW was delisted on the 30th of October, 2025.
43 hedge funds and large institutions have $2.19M invested in CERo Therapeutics Warrants in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
8% more capital invested
Capital invested by funds: $2.03M → $2.19M (+$153K)
7% less funds holding
Funds holding: 46 → 43 (-3)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
70% less call options, than puts
Call options by funds: $7K | Put options by funds: $23K
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$2.17K |
| 2 |
RCM
Robinson Capital Management
Grosse Pointe Farms,
Michigan
|
+$159 |
| 3 |
CS
Clear Street
New York
|
+$88 |
| 4 |
HF
HRT Financial
New York
|
+$15 |
| 5 |
Walleye Capital
New York
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$16.3K |
| 2 |
SRCM
Sage Rock Capital Management
New York
|
-$3.69K |
| 3 |
DCM
Difesa Capital Management
New York
|
-$2.51K |
| 4 |
SG
StoneX Group
New York
|
-$911 |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$778 |
CEROW Hedge Fund Activity: Q2 2023 in Review
43 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q2 2023, worth a combined $2.19M — up 7.5% from $2.03M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CEROW and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Yakira Capital Management, opening a new position worth an estimated $2.17K. The largest seller was Shaolin Capital Management, exiting entirely with an estimated $16.3K sold.
- 43 institutional investors held CERo Therapeutics Warrants (CEROW) as of Q2 2023, down from 46 in Q1 2023.
- Funds reported $2.19M of CERo Therapeutics Warrants stock for Q2 2023, up 7.5% quarter-over-quarter.
- 1 fund opened new CERo Therapeutics Warrants positions in Q2 2023 and 4 closed out, a net change of -3 holders.
- The largest CERo Therapeutics Warrants buyer in Q2 2023 was Yakira Capital Management, an estimated $2.17K added.
- The largest CERo Therapeutics Warrants seller in Q2 2023 was Shaolin Capital Management, an estimated $16.3K sold.
Based on aggregated 13F filings for Q2 2023.